Literature DB >> 16914770

The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux.

Leonid Gaidukov1, Mira Rosenblat, Michael Aviram, Dan S Tawfik.   

Abstract

Serum paraoxonase (PON1) is a HDL-associated enzyme exhibiting potentially antiatherogenic properties. Here, we examined the common PON1-192R/Q human polymorphism. Despite numerous studies, the effect of this polymorphism on the antiatherogenic potential of PON1 is yet unresolved. Our structural model suggests that amino acid 192 constitutes part of the HDL-anchoring surface and active site of PON1. Based on our findings that PON1 is an interfacially activated lipolactonase that selectively binds HDL carrying apolipoprotein A-I (apoA-I) and is thereby greatly stabilized and catalytically activated, we examined the interaction of the PON1-192 isozymes with reconstituted HDL-apoA-I particles. We found that PON1 position 192 is indeed involved in HDL binding. The PON1-192Q binds HDL with a 3-fold lower affinity than the R isozyme and consequently exhibits significantly reduced stability, lipolactonase activity, and macrophage cholesterol efflux. We also observed the lower affinity and stability of the 192Q versus the 192R isozyme in sera of individuals belonging to the corresponding genotypes. The observed differences in the properties of PON1-192R/Q isozymes provide a basis for further analysis of the contribution of the 192R/Q polymorphism to the susceptibility to atherosclerosis, although other factors, such as the overall levels of PON1, may play a more significant role.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914770     DOI: 10.1194/jlr.M600297-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

1.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

2.  Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects.

Authors:  Soudabeh Fallah; Morteza Seifi; Asghar Ghasemi; Mohsen Firoozrai; Ali Samadikuchaksaraei
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 3.  Paraoxonases: metabolic role and pharmacological projection.

Authors:  Carlos Moya; Salvador Máñez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

4.  PON1 multitasks to protect health.

Authors:  Janice E Chambers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

5.  Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men.

Authors:  Kenneth J Mukamal; Jennifer K Pai; Majken K Jensen; Eric B Rimm
Journal:  Circ J       Date:  2009-05-15       Impact factor: 2.993

6.  Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone.

Authors:  John F Teiber; Sven Horke; Donovan C Haines; Puneet K Chowdhary; Junhui Xiao; Gerald L Kramer; Robert W Haley; Dragomir I Draganov
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

7.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

Authors:  Tamali Bhattacharyya; Stephen J Nicholls; Eric J Topol; Renliang Zhang; Xia Yang; David Schmitt; Xiaoming Fu; Mingyuan Shao; Danielle M Brennan; Stephen G Ellis; Marie-Luise Brennan; Hooman Allayee; Aldons J Lusis; Stanley L Hazen
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

8.  Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Authors:  M Mastorikou; B Mackness; Y Liu; M Mackness
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

9.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17

10.  Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?

Authors:  Kimberly A Davis; J Allen Crow; Howard W Chambers; Edward C Meek; Janice E Chambers
Journal:  Environ Health Perspect       Date:  2009-03-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.